The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
20-Jun-23
Pending
$595 million
Target:
Lookers Plc
Acquiror:
Alpha Auto Group
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
29-Nov-22
Undisclosed
Target:
Staff Brain Co., Ltd. And Technobrain Co., Ltd.
Acquiror:
World Co., LTD.
World Co., LTD. ("World"), a regional staffing company in Japan, acquired Brain Group (Staff Brain Co., Ltd. and Technobrain Co., Ltd.), regional staffing companies in Japan
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
08-Aug-22
Undisclosed
Target:
UK Operations of Lion Pty Limited
Acquiror:
Odyssey Inns Ltd
Advised Lion Pty Limited, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings Co., Ltd., on the divestment of its UK operations to Odyssey Inns Ltd.
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
07-Dec-21
Pending
Undisclosed
Target:
Interamericana Trading Corporation and Simpson Motors
Acquiror:
Inchcape plc
Advising Inchcape plc, the leading independent global automotive distributor, on the acquisition of Interamericana Trading Corporation (“ITC”), a leading independent automotive distributor in the Caribbean region, and Simpson Motors, the leading automotive retailer in Barbados, from the Simpson Group
07-Dec-21
$153 million
Target:
Japan Medical Dynamic Marketing
Acquiror:
Mitsui Chemicals
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
10-Nov-21
Undisclosed
Target:
Bell's Brewery
Acquiror:
Lion / Kirin
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
27-Jul-21
Undisclosed
Target:
Pulsant Limited
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
12-Jul-21
Pending
$1.7 billion
Target:
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
Acquiror:
KPS Capital Partners
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
07-Jun-21
Undisclosed
Target:
Rights to General, Right Guard and Dry Idea brands
Acquiror:
N/A
Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)
27-May-21
$1.4 billion
Target:
Equiniti Group PLC
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
23-Nov-20
$120 million
Target:
Greencore Group plc
Acquiror:
N/A
Advised Greencore Group plc, a leading UK manufacturer of convenience foods based in Ireland, on its £90mm non pre-emptive equity placing